# Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

> **NCT02242812** · PHASE4 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Metoprolol succinate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02242812
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-09
- **Primary completion:** 2004-10
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02242812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02242812, "Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02242812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*